Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma
| Autor: | Koeppen, Susanne, Verstappen, C.C.P., Körte, R., Scheulen, Max Ernst, Strumberg, Dirk, Postma, T.J., Heimans, J.J., Huijgens, P.C., Kiburg, B., Renzing-Köhler, K., Diener, Hans Christoph, K�rte, R., Renzing-K�hler, K. |
|---|---|
| Přispěvatelé: | VU University medical center |
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Vincristine Randomization medicine.medical_treatment Medizin Placebo law.invention Cohort Studies Interviews as Topic Placebos Randomized controlled trial Adrenocorticotropic Hormone Double-Blind Method law Internal medicine Antineoplastic Combined Chemotherapy Protocols Medicine Humans Longitudinal Studies Aged Chemotherapy business.industry Lymphoma Non-Hodgkin General Medicine Middle Aged medicine.disease Hodgkin Disease Peptide Fragments Surgery Discontinuation Non-Hodgkin's lymphoma Oncology Anticonvulsants Female Nervous System Diseases business Cohort study medicine.drug |
| Zdroj: | Journal of Cancer Research and Clinical Oncology, 130(3), 153-60. Springer Verlag Koeppen, S, Verstappen, CC, Korte, R, Scheulen, ME, Strumberg, D, Postma, T J, Heimans, J J, Huijgens, P C, Kiburg, B, Renzing-Kohler, K & Diener, HC 2004, ' Lack of neuroprotection by an ACTH (4-9) analogue. A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma. ', Journal of Cancer Research and Clinical Oncology, vol. 130, no. 3, pp. 153-60 . https://doi.org/10.1007/s00432-003-0524-9 |
| ISSN: | 0171-5216 |
| DOI: | 10.1007/s00432-003-0524-9 |
| Popis: | This randomized, double-blind, placebo-controlled study evaluates the effect of the corticotropin (4–9) analogue Org 2766 on the neuropathy-free interval in patients receiving vincristine (VCR) containing chemotherapy for Hodgkin’s or non-Hodgkin’s lymphoma. In a longitudinal design, 150 patients were evaluated by interview, neurological examination, and neurophysiological techniques. Patients with an expected cumulative VCR dose of at least 8 mg received a single dose of Org 2766 or placebo before and after each intravenous VCR injection and 3–4 weeks after cessation of VCR. The final patient assessment was performed 1 month after discontinuation of study medication. The neuropathy-free interval as the major end point of this study was defined as the first occurrence of bilateral paresthesias and expressed as the administered cumulative VCR dose. This bi-center study represents the largest cohort of patients monitored for the effect of an ACTH-analogue on VCR neurotoxicity. A total of 147 patients were included in the final analysis. No significant differences were observed between the placebo and actively treated group for the major and secondary endpoints. Contrary to a single previous pilot study in patients receiving VCR-based chemotherapy, in our study the ACTH (4–9) analogue Org 2766 did not provide protection from VCR-induced neuropathy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink